Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study
Abstract Background Hypertension is a major cause of cardiac dysfunction. The earliest manifestation is left ventricular remodeling/hypertrophy. The occurrence of adverse cardiac remodeling and outcomes occurs irrespective of age in blacks. This necessitated an estimate of the prevalence of left ven...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-025-04470-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545015946379264 |
|---|---|
| author | Busayo Onafowoke Oguntola Stephen Olawale Oguntola Opeyemi Ezekiel Ojo Pauleen Ayomide Ukpabio Adams Olalekan Omoaghe Kehinde Samuel Olaniyi |
| author_facet | Busayo Onafowoke Oguntola Stephen Olawale Oguntola Opeyemi Ezekiel Ojo Pauleen Ayomide Ukpabio Adams Olalekan Omoaghe Kehinde Samuel Olaniyi |
| author_sort | Busayo Onafowoke Oguntola |
| collection | DOAJ |
| description | Abstract Background Hypertension is a major cause of cardiac dysfunction. The earliest manifestation is left ventricular remodeling/hypertrophy. The occurrence of adverse cardiac remodeling and outcomes occurs irrespective of age in blacks. This necessitated an estimate of the prevalence of left ventricular hypertrophy (LVH) and an assessment of the roles of the mammalian target organ of rapamycin (mTOR) and angiotensin-II (Ang II) as possible pathogenic markers of LVH among young hypertensives. Methods This prospective case-control study involved 110 hypertensive and 60 normotensive (control) participants aged 18–45 across tertiary hospitals in Ekiti state. Ethical approval was obtained from all the various institutions. Participants were recruited consecutively after giving informed consent. Sociodemographic/clinical information, resting electrocardiogram and echocardiography were obtained. Venous blood was obtained to estimate mTOR, Ang II, Chemerin, lipids – triglyceride (TG), high-density lipoprotein (HDL), total cholesterol (TC), troponin-T, NF-Kβ, and Galectin-3 using enzyme-linked immunosorbent assay. Results The prevalence of LVH among the hypertensive group was 20.9%, 39%, 11.01%, and 15.74% using 2D-transthoracic echocardiography, Sokolow-Lyon, Cornell’s and Cornell product ECG criteria. Also, hypertensives with LVH had a significantly increased blood pressure, body mass index, serum level of TG, TG/HDL, TC/HDL, chemerin, troponin T, Galectin-3 and total mTOR compared to normotensive and hypertensives without LVH. At the same time, serum NF-kβ and Ang II were only significant when compared with normotensive but not hypertensives without LVH. The total mTOR moderately correlated positively with ANG-II. Conclusions The results suggest an interaction between mTOR and Ang II in the development of LVH. In addition, it shows that LVH is associated with dyslipidemia, inflammation, and fibrosis. |
| format | Article |
| id | doaj-art-f5f923967efd4e19aa6f6d5d7850adf6 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-f5f923967efd4e19aa6f6d5d7850adf62025-01-12T12:07:14ZengBMCBMC Cardiovascular Disorders1471-22612025-01-012511910.1186/s12872-025-04470-9Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control studyBusayo Onafowoke Oguntola0Stephen Olawale Oguntola1Opeyemi Ezekiel Ojo2Pauleen Ayomide Ukpabio3Adams Olalekan Omoaghe4Kehinde Samuel Olaniyi5Department of Internal Medicine, ABUAD Multisystem Hospital, Afe Babalola UniversityDepartment of Internal Medicine, ABUAD Multisystem Hospital, Afe Babalola UniversityDepartment of Medicine, College of Medicine, Ekiti State UniversityDepartment of Internal Medicine, ABUAD Multisystem Hospital, Afe Babalola UniversityCardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola UniversityCardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola UniversityAbstract Background Hypertension is a major cause of cardiac dysfunction. The earliest manifestation is left ventricular remodeling/hypertrophy. The occurrence of adverse cardiac remodeling and outcomes occurs irrespective of age in blacks. This necessitated an estimate of the prevalence of left ventricular hypertrophy (LVH) and an assessment of the roles of the mammalian target organ of rapamycin (mTOR) and angiotensin-II (Ang II) as possible pathogenic markers of LVH among young hypertensives. Methods This prospective case-control study involved 110 hypertensive and 60 normotensive (control) participants aged 18–45 across tertiary hospitals in Ekiti state. Ethical approval was obtained from all the various institutions. Participants were recruited consecutively after giving informed consent. Sociodemographic/clinical information, resting electrocardiogram and echocardiography were obtained. Venous blood was obtained to estimate mTOR, Ang II, Chemerin, lipids – triglyceride (TG), high-density lipoprotein (HDL), total cholesterol (TC), troponin-T, NF-Kβ, and Galectin-3 using enzyme-linked immunosorbent assay. Results The prevalence of LVH among the hypertensive group was 20.9%, 39%, 11.01%, and 15.74% using 2D-transthoracic echocardiography, Sokolow-Lyon, Cornell’s and Cornell product ECG criteria. Also, hypertensives with LVH had a significantly increased blood pressure, body mass index, serum level of TG, TG/HDL, TC/HDL, chemerin, troponin T, Galectin-3 and total mTOR compared to normotensive and hypertensives without LVH. At the same time, serum NF-kβ and Ang II were only significant when compared with normotensive but not hypertensives without LVH. The total mTOR moderately correlated positively with ANG-II. Conclusions The results suggest an interaction between mTOR and Ang II in the development of LVH. In addition, it shows that LVH is associated with dyslipidemia, inflammation, and fibrosis.https://doi.org/10.1186/s12872-025-04470-9Angiotensin IIEchocardiographyHypertensionLeft ventricular hypertrophyMammalian target organ of rapamycin |
| spellingShingle | Busayo Onafowoke Oguntola Stephen Olawale Oguntola Opeyemi Ezekiel Ojo Pauleen Ayomide Ukpabio Adams Olalekan Omoaghe Kehinde Samuel Olaniyi Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study BMC Cardiovascular Disorders Angiotensin II Echocardiography Hypertension Left ventricular hypertrophy Mammalian target organ of rapamycin |
| title | Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study |
| title_full | Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study |
| title_fullStr | Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study |
| title_full_unstemmed | Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study |
| title_short | Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study |
| title_sort | left ventricular hypertrophy in young hypertensives the possible crosstalk of mtor and angiotensin ii a case control study |
| topic | Angiotensin II Echocardiography Hypertension Left ventricular hypertrophy Mammalian target organ of rapamycin |
| url | https://doi.org/10.1186/s12872-025-04470-9 |
| work_keys_str_mv | AT busayoonafowokeoguntola leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy AT stephenolawaleoguntola leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy AT opeyemiezekielojo leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy AT pauleenayomideukpabio leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy AT adamsolalekanomoaghe leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy AT kehindesamuelolaniyi leftventricularhypertrophyinyounghypertensivesthepossiblecrosstalkofmtorandangiotensiniiacasecontrolstudy |